BRPI0411289A - polipeptìdeos de fusão da variante da glicoproteìna ib alfa de plaquetas e métodos do seu uso - Google Patents

polipeptìdeos de fusão da variante da glicoproteìna ib alfa de plaquetas e métodos do seu uso

Info

Publication number
BRPI0411289A
BRPI0411289A BRPI0411289-0A BRPI0411289A BRPI0411289A BR PI0411289 A BRPI0411289 A BR PI0411289A BR PI0411289 A BRPI0411289 A BR PI0411289A BR PI0411289 A BRPI0411289 A BR PI0411289A
Authority
BR
Brazil
Prior art keywords
variant
methods
fusion polypeptides
platelet glycoprotein
variant fusion
Prior art date
Application number
BRPI0411289-0A
Other languages
English (en)
Inventor
Gray Shaw
Dianne S Sako
Ravindra Kumar
Jin Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0411289A publication Critical patent/BRPI0411289A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"POLIPEPTìDEOS DE FUSãO DA VARIANTE DA GLICOPROTEìNA IB ALFA DE PLAQUETAS E MéTODOS DO SEU USO". A presente invenção propõe composições e métodos para o tratamento ou prevenção de distúrbios associados com problemas vasculares.
BRPI0411289-0A 2003-06-11 2004-06-14 polipeptìdeos de fusão da variante da glicoproteìna ib alfa de plaquetas e métodos do seu uso BRPI0411289A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47752503P 2003-06-11 2003-06-11
PCT/US2004/019057 WO2004111089A2 (en) 2003-06-11 2004-06-14 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0411289A true BRPI0411289A (pt) 2006-08-01

Family

ID=33551724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411289-0A BRPI0411289A (pt) 2003-06-11 2004-06-14 polipeptìdeos de fusão da variante da glicoproteìna ib alfa de plaquetas e métodos do seu uso

Country Status (15)

Country Link
US (2) US7727535B2 (pt)
EP (2) EP2522677A1 (pt)
JP (1) JP2007537710A (pt)
KR (1) KR20060022261A (pt)
CN (1) CN100436480C (pt)
AU (1) AU2004247737B2 (pt)
BR (1) BRPI0411289A (pt)
CA (1) CA2530972A1 (pt)
IL (2) IL172337A (pt)
MX (1) MXPA05013509A (pt)
NO (1) NO20060093L (pt)
NZ (1) NZ544165A (pt)
RU (1) RU2403262C2 (pt)
WO (1) WO2004111089A2 (pt)
ZA (1) ZA200510331B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DE102007031708A1 (de) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
WO2009026551A1 (en) 2007-08-23 2009-02-26 Bloodcenter Of Wisconsin, Inc. Methods and kits for measuring von willebrand factor
CN103930123B (zh) * 2011-11-15 2016-11-09 沃尔特及伊莱萨霍尔医学研究院 可溶性介体
EP2794007A4 (en) * 2011-12-23 2015-11-18 Vasculogics Inc COMPOSITIONS AND METHODS FOR TREATING THROMBOSES AND EXTENDING THE LIFE OF THE STORED THROMBOCYTES
ES2614352T3 (es) 2014-03-11 2017-05-30 Siemens Healthcare Diagnostics Products Gmbh Método para la detección de moduladores de la interacción de GPIb-trombina
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
EP3555123B1 (en) * 2018-02-20 2024-03-27 F. Hoffmann-La Roche AG Composition comprising recombinant gpiba receptor protein
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (en) * 2021-07-29 2023-02-02 The University Of Birmingham Protein interaction inhibitors
EP4455160A4 (en) * 2021-12-15 2025-12-10 Shanghai Synvida Biotechnology Co Ltd PRODUCT AND METHOD OF TREATMENT FOR THROMBOCYTOPENIA
CN121319216A (zh) * 2025-10-17 2026-01-13 安康市中心医院 一种靶向性硒偶联抗炎融合蛋白及其在急性冠脉综合征再灌注损伤修复中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340727A (en) 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
IL88308A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
US4899195A (en) * 1988-01-29 1990-02-06 Ushio Denki Method of exposing a peripheral part of wafer
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US5194743A (en) * 1990-04-06 1993-03-16 Nikon Corporation Device for positioning circular semiconductor wafers
JP2874280B2 (ja) * 1990-05-16 1999-03-24 株式会社ニコン 周縁露光装置及び周縁露光方法
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5317097A (en) 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
TW316322B (pt) * 1995-10-02 1997-09-21 Ushio Electric Inc
JP3237522B2 (ja) * 1996-02-05 2001-12-10 ウシオ電機株式会社 ウエハ周辺露光方法および装置
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
EP1074564B1 (en) 1998-04-23 2008-12-10 Ajinomoto Co., Inc. Substance with antithrombotic activity and method for detecting glycokallidin
AR035779A1 (es) * 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos

Also Published As

Publication number Publication date
EP1636266A2 (en) 2006-03-22
CA2530972A1 (en) 2004-12-23
JP2007537710A (ja) 2007-12-27
IL172337A (en) 2012-07-31
AU2004247737B2 (en) 2009-04-23
WO2004111089A3 (en) 2005-05-12
KR20060022261A (ko) 2006-03-09
US20110039780A1 (en) 2011-02-17
CN100436480C (zh) 2008-11-26
AU2004247737A1 (en) 2004-12-23
ZA200510331B (en) 2007-03-28
EP2522677A1 (en) 2012-11-14
MXPA05013509A (es) 2006-04-05
CN1823090A (zh) 2006-08-23
NZ544165A (en) 2008-12-24
US7727535B2 (en) 2010-06-01
NO20060093L (no) 2006-03-01
RU2006100306A (ru) 2006-06-10
WO2004111089A2 (en) 2004-12-23
IL220272A0 (en) 2012-07-31
US20050089888A1 (en) 2005-04-28
HK1095152A1 (zh) 2007-04-27
RU2403262C2 (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
DE69907137D1 (de) Autoklavierbare pharmazeutische zusammensetzungen mit komplexbildner
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
BR0011433A (pt) Imidazoquinolinas substituìdas com sulfonamida e sulfamida
ECSP045154A (es) Composiciones de fórmula para infantes que comrende cantidades aumentadas de alfa - lactalbumin
DE60335282D1 (de) Polycarbonatharzzusammensetzung und formkörper daraus
BR0212951A (pt) Formas de dosagens compósitas
BRPI0401482A (pt) Bico de mamadeira
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
DOP2002000429A (es) Imidazotriazinas
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
DE60227170D1 (de) Flammwidrige harzzusammensetzung und formkörper daraus
BR0207039A (pt) Polipeptìdeos de fusão da glicoproteìna ib alfa plaquetária e seus métodos de uso
BR9902837A (pt) Corpo sìncrono com peça de pressão ou elemento de encaixe integrado
BR0013110A (pt) Forma oral de administração contendo microorganismos probióticos
BR9807655A (pt) Uso de inibidores de lipase gastrintestinal.
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
WO2004111089A3 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
BR0313611A (pt) Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica
BR9913073A (pt) Utilização de partìculas de dióxido de titânio, composição de borracha à base de pelo menos um elastÈmero, e, artigo acabado
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DE10297668D2 (de) Mit Vitalelementen und/oder Schutzstoffen angereicherte troposphärische Raumelemente
BR0307048A (pt) Composição farmacêutica orodispersìvel de perindoprila
BR0317689A (pt) Composições compreendendo n-isopropilacrilamida e métodos para inibição de adsorção de protéina sobre superfìcies
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
MX9405371A (es) Derivado de naftilo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.